Katharina G.
- Country
- Germany
- Department
- Hämatologie/Onkologie
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 210 of 365 partner sites.
Specializations
Myeloid Malignancies
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with particular focus on various risk categories and genetic mutations.
- Lower-risk MDS treatments
- Higher-risk MDS management
- AML with genetic mutations
Expertise includes treating both newly diagnosed and relapsed/refractory cases using novel therapeutic approaches.
Novel Therapeutic Approaches
Focus on innovative treatment strategies incorporating targeted therapies and combination treatments for hematologic conditions.
- Venetoclax-based therapies
- Luspatercept applications
- IDH1 inhibitor treatments
Special interest in developing treatments for patients ineligible for intensive chemotherapy.
Specialized Conditions
Expert in treating rare and complex hematologic disorders including VEXAS syndrome and therapy-related myeloid neoplasms.
- Transfusion-dependent anemias
- Genetic mutation-specific treatments
- Chronic myelomonocytic leukemia
Focuses on personalized treatment approaches based on molecular and genetic profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.